Results 41 to 50 of about 5,853 (155)

In Vitro Activity of Rifabutin and Rifampin against Antibiotic-Resistant Acinetobacter baumannii, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae

mSphere, 2021
We recently reported that the antimicrobial activity of rifabutin against Acinetobacter baumannii is best modeled by the use of RPMI for in vitro susceptibility testing.
Bosul Lee, Jun Yan, Amber Ulhaq, Sarah Miller, Wonjae Seo, Peggy Lu, Rosemary She, Brad Spellberg, Brian Luna   +8 more
doaj   +1 more source

A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients

British Journal of Clinical Pharmacology, EarlyView.
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly ...
Clara Laffitte Redondo, Venceslas Bourdin, Abd El Kader Ait Tayeb, Sihem Benaboud, Inès Martins, Caroline Joyau, Myriam Benhamida, Isabelle Sermet‐Gaudelus, Clémence Martin, Pierre Régis Burgel, Céline Verstuyft, Laurent Chouchana, Estelle Ayme‐Dietrich   +12 more
wiley   +1 more source

Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease

The Journal of Dermatology, EarlyView.
ABSTRACT Certain psoriatic disease treatments, including tumor necrosis factor‐α inhibitors (TNFi), increase tuberculosis (TB) risk. Testing for latent TB infection (LTBI) before initiating systemic therapy has been standard practice for psoriasis (PsO) patients; however, updated consensus states routine testing is not required before initiating ...
Luis Puig, Tsen‐Fang Tsai, Enrique R. Soriano, Tina Bhutani, Megan Miller, Alexa P. Kollmeier, Shu Li, Hewei Li, Sarah Ofori, Jeffrey Pawlikowski, Elizabeth Adamson, Melinda Gooderham, Angela Londoño Garcia, Mark Lebwohl, Peter Nash   +14 more
wiley   +1 more source

Successful Anticoagulation With Warfarin After Switching From Rifampin to Rifabutin

Journal of Primary Care & Community Health, 2023
Purpose: A case of a patient receiving warfarin for pulmonary embolism (PE) concomitantly with rifampin for treatment of active pulmonary tuberculosis (PTB) is presented.
Marwah E. Alnewais, Samantha L. Landolfa, Madelyne Bean, Joli D. Fermo   +3 more
doaj   +1 more source

Caenorhabditis elegans as an in vivo model system for human inherited primary arrhythmia syndromes

The Journal of Physiology, EarlyView.
Abstract figure legend Most genes involved in inherited primary arrhythmia syndromes (IPAS) are conserved in Caenorhabditis elegans, where genetic manipulation enables functional characterization of variants, identification of regulatory proteins, and in vivo drug testing.
Antoine Delinière, Thomas Boulin, Maëlle Jospin, Alexandre Janin, Gilles Millat, Philippe Chevalier, Olga Andrini   +6 more
wiley   +1 more source

Host–Pathogen Dual Targeting With Repurposed Drugs Identifies a Synergistic Therapy for Intracellular Staphylococcus aureus

MicrobiologyOpen, Volume 15, Issue 3, June 2026.
A large intracellular drug‐repurposing screen identifies a potent synergy between 5‐fluoro‐2′‐deoxycytidine and rifapentine, acting through dual host–pathogen targeting to reduce Staphylococcus aureus burdens across strains, cell types, and infection models (created with BioRender).
Blanca Lorente‐Torres, Helena Á. Ferrero, Pablo Castañera, Jesús Llano‐Verdeja, Sergio Fernández‐Martínez, Amanda Herrero‐González, Farzaneh Javadimarand, Roberto López, Jesús F. Aparicio, Andrew M. Edwards, Volker Behrends, Luis M. Mateos, Álvaro Mourenza, Michal Letek   +13 more
wiley   +1 more source

CRISPR Interference-Based Inhibition of MAB_0055c Expression Alters Drug Sensitivity in Mycobacterium abscessus

Microbiology Spectrum, 2023
There is an unmet medical need for effective treatments against Mycobacterium abscessus infections. Although advanced molecular genetic tools to validate drug targets and resistance of M. abscessus exist, the practical design and construction of plasmids
Thanh Quang Nguyen, Bo Eun Heo, Yujin Park, Seunghyeon Jeon, Arunima Choudhary, Cheol Moon, Jichan Jang   +6 more
doaj   +1 more source

Diagnostic and Therapeutic Dilemmas in Recurrent Pulmonary Alveolar Proteinosis After Bilateral Lung Transplantation

Respirology Case Reports, Volume 14, Issue 6, June 2026.
Pulmonary alveolar proteinosis (PAP) is an ultra‐rare lung disease that can recur even years after bilateral lung transplantation, as in this 73‐year‐old man whose diagnosis was delayed by PAS‐negative BAL and overlapping opportunistic infections (Nocardia, MAC, Aspergillus). Despite initially normal post‐transplant spirometry, he developed progressive
Omar Lopez, Deven Gupta, Shreya Podder, Ajay Wagh   +3 more
wiley   +1 more source

A rare case of pulmonary mycobacteriosis caused by rifabutin resistant Mycobacterium celatum and review of the literature

Respiratory Medicine Case Reports, 2019
The present case demonstrates an atypical pulmonary mycobacteriosis that mimicked classical symptoms and radiology findings for tuberculosis. While T-SPOT Test and PCR analyses proved negative for tuberculosis, microscopic sputum evaluation showed acid ...
Marcela Doktorova Demmin, Adrian Gillissen   +1 more
doaj   +1 more source

Comparison of eradication rates of moxifloxacin–rifabutin triple therapy and bismuth quadruple therapy as second‐line regimens in patients with peptic ulcers

Health Science Reports, 2022
Background Bismuth quadruple (BQ) therapy is known to have poor patient compliance and a complex dosing method, and no appropriate third‐line regimen exists if second‐line BQ therapy fails.
Chang Min Lee, Seong Je Kim, Se In Hah, Ji Yoon Kwak, Jung Woo Choi, Hyun Chin Cho, Chang Yoon Ha, Ok Jae Lee, Woon Tae Jung   +8 more
doaj   +1 more source